Baekje Shenzhou Zebtinib ALPINE Research Appears 2023 ASH Latest Follow up Data shows Continuous Benefits
杨小宝1
发表于 2023-12-13 14:24:03
1254
0
0
From December 9th to 11th, as one of the largest academic events in the world of hematology, the American Society of Hematology (ASH) Annual Conference was successfully held. During this conference, a total of 24 papers from Baekje were included, of which 3 were presented orally. With the release of multiple research results, BeiGene's core self-developed product, Baiyue Ze& Reg; The advantages of Zebutinib as the best BTK inhibitor of its kind have once again been recognized by the international academic community. At the same time, BeiGene's other two independently developed differentiated BCL-2 inhibitors, sonrotoclax and BTK CDAC BGB-16673, have also achieved excellent research data in clinical trials, further demonstrating BeiGene's leading position and strong potential in the treatment of blood tumors.
At this ASH conference, BeiGene announced three important data presentations for Zebutinib, including the 3-year follow-up results of three global "head to head" ALPINE studies. Data shows that in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients, at a median follow-up of 39 months, Zebutinib showed a sustained progression free survival (PFS) advantage over Ibrutinib, with 3-year PFS rates of 64.9% and 54.8%, respectively (HR: 0.68; P=0.0011).
The extended follow-up of the ALPINE study released this time suggests that the 3-year OS rate of the Zebutinib group is higher than that of the control group. The 3-year OS rates of the Zebutinib and Ibrutinib groups were 82.5% and 79.6%, respectively. The Zebutinib group showed a potentially better OS trend, and the Zebutinib group had fewer deaths (HR: 0.75; p=0.098). In addition, compared to Ibrutinib, Zebutinib continues to demonstrate more favorable safety and tolerability.
Thanks to the advancement of treatment methods, the overall survival (OS) of CLL patients is usually longer, so PFS has become the "gold standard" in clinical trials, and OS itself is not the main endpoint. After a follow-up period of more than 3 years, ALPINE data once again proves that Zebutinib has better efficacy and superior safety characteristics compared to Ibrutinib. Based on positive data from two global phase 3 clinical trials, including the ALPINE study, the US FDA has fully approved Zebutinib for the treatment of adult patients with CLL/SLL.
Based on its outstanding and long-lasting safety and efficacy demonstrated in various indications such as head to head research, Zebutinib continues to deepen its global commercialization map and has been approved in over 65 international markets. It is also the most approved and widely deployed BTK inhibitor with the most indications. In the first three quarters of 2023, the total global sales of Zebutinib amounted to 877 million US dollars. According to third-party forecasts, Zebutinib is expected to become a new "1 billion US dollar molecule" this year.
At this year's ASH conference, BeiGene also showcased the clinical progress of its core products, including the BCL-2 inhibitor sonrotoclax and BTK CDAC BGB-16673, which further solidified the company's leading position in the field of hematology.
As a potential "best in class" BCL-2 inhibitor, sonrotocrax has a shorter half-life and no drug accumulation compared to the already marketed BCL-2 inhibitor, which is expected to bring better safety features. At present, Sonrotoclax has a wide clinical layout, with over 600 patients enrolled in clinical trials, and has achieved differentiated effectiveness and safety in various indications.
With its differentiated innovation pipeline, strong global development capabilities, and broad clinical layout, BeiGene has established a comprehensive and integrated global independent capability, accelerating the development of innovative drugs, expanding drug accessibility, and entering the next wave of innovative research and development. (Yan Yun)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- US March retail sales data exceeding expectations or further delaying Fed rate cuts
- After market drop of nearly 5%! Netflix's Q1 performance exceeded expectations and will no longer release new user data starting next year
- Anonymous processing of facial information outside the car, default not to collect cabin data Tesla meets automotive data security compliance requirements! Various regions have gradually lifted restrictions on travel
- Luckin Coffee v. Shenzhou Youche Case Goes to Court Today
- BeiGene: First quarter loss of 1.908 billion yuan
- "Never go against the Federal Reserve"? NO! Currently, Wall Street is more inclined to oppose data and bias
- BeiGene: Chief Financial Officer Wang Aijun Resigns, Aaron Rosenberg Takes Over
- BeiGene (688235. SH): Chief Financial Officer Wang Aijun resigns due to seeking external development opportunities
- BeiGene Chief Financial Officer Resigns, Aaron Rosenberg Takes Over
- LeXin releases consumer protection report: 148 million data security attacks intercepted within the year
-
【ゆとりサイクルが始まった!歴史を鑑とする:FED金利調整と大統領選結果には“隠れた関連”があった】データによると、選挙日前に金利が引き上げられた5年間で、大統領やホワイトハウスを支配していた政党が4年連 ...
- 不正经的工程师
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
【トヨタが米国で約4万2000台のカローラCrossをリコール】トヨタ自動車は当時時間9月20日、2022年6月から2024年9月までに生産された一部のカローラCrossハイブリッド車を安全にリコールしていると発表した。リコー ...
- 伍六三
- 昨天 09:38
- 支持
- 反对
- 回复
- 收藏
-
アイルランドのライアン航空のオリーリ最高経営責任者は現地時間9月14日、最近のボーイング社員のストライキが、2025年夏までにライアン社に納入されるボーイング737 MAX機の数に影響を与える可能性があると述べた ...
- rlf2000
- 昨天 20:49
- 支持
- 反对
- 回复
- 收藏
-
インテルは9月19日、イスラエルの自動運転技術会社Mobileyeの大株主として、ビジネスの将来に自信を持っており、現在、同社の株式の多数を切り離す計画はないと発表した。 ...
- hecgdge4
- 3 天前
- 支持
- 反对
- 回复
- 收藏